Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Cash & Current Investments: 2012-2025

Historic Cash & Current Investments for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to $630.2 million.

  • Ascendis Pharma A's Cash & Current Investments fell 8.26% to $630.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 billion, marking a year-over-year increase of 33.79%. This contributed to the annual value of $605.6 million for FY2024, which is 40.92% up from last year.
  • Per Ascendis Pharma A's latest filing, its Cash & Current Investments stood at $630.2 million for Q3 2025, which was up 12.69% from $559.2 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Cash & Current Investments registered a high of $1.2 billion during Q1 2022, and its lowest value of $278.6 million during Q2 2024.
  • Over the past 3 years, Ascendis Pharma A's median Cash & Current Investments value was $544.8 million (recorded in 2025), while the average stood at $515.4 million.
  • As far as peak fluctuations go, Ascendis Pharma A's Cash & Current Investments skyrocketed by 191.43% in 2021, and later slumped by 55.78% in 2023.
  • Over the past 5 years, Ascendis Pharma A's Cash & Current Investments (Quarterly) stood at $780.3 million in 2021, then decreased by 3.83% to $750.3 million in 2022, then crashed by 42.72% to $429.8 million in 2023, then surged by 39.13% to $597.9 million in 2024, then fell by 8.26% to $630.2 million in 2025.
  • Its Cash & Current Investments stands at $630.2 million for Q3 2025, versus $559.2 million for Q2 2025 and $544.8 million for Q1 2025.